Enovis Corporation (NYSE:ENOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Enovis Corporation (NYSE:ENOV) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $45.1667.

A number of research analysts recently issued reports on ENOV shares. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Sunday. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Evercore reiterated an “outperform” rating and set a $36.00 target price on shares of Enovis in a research report on Friday. Finally, Needham & Company LLC boosted their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert acquired 1,000 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the acquisition, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 5,000 shares of company stock worth $121,983 in the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after buying an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the last quarter. Rubric Capital Management LP acquired a new position in Enovis during the third quarter worth $83,435,000. River Road Asset Management LLC raised its holdings in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after buying an additional 46,289 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its holdings in Enovis by 41.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock worth $34,913,000 after buying an additional 326,900 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 2.7%

Enovis stock opened at $26.52 on Friday. The company has a quick ratio of 1.04, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. Enovis has a 12-month low of $21.00 and a 12-month high of $37.85. The firm’s fifty day moving average is $23.86 and its 200 day moving average is $25.80. The company has a market capitalization of $1.53 billion, a PE ratio of -1.33 and a beta of 1.41.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the previous year, the company earned $0.81 EPS. Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts predict that Enovis will post 3.62 EPS for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.